학술논문
Extracellular matrix turnover proteins as risk markers in people with type 2 diabetes and microalbuminuria.
Document Type
Academic Journal
Author
Skriver-Møller AC; Steno Diabetes Center, Copenhagen, Denmark. Electronic address: anne-cathrine.skriver-moeller.01@regionh.dk.; Møller AL; Nordic Bioscience, Herlev, Denmark.; Blond MB; Steno Diabetes Center, Copenhagen, Denmark.; Rasmussen DGK; Nordic Bioscience, Herlev, Denmark.; Genovese F; Nordic Bioscience, Herlev, Denmark.; Reinhard H; Steno Diabetes Center, Copenhagen, Denmark.; von Scholten BJ; Steno Diabetes Center, Copenhagen, Denmark; Novo Nordisk A/S, Søborg, Denmark; Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Denmark.; Jacobsen PK; Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark.; Parving HH; Department of Endocrinology, Rigshospitalet, University of Copenhagen, Denmark.; Karsdal MA; Nordic Bioscience, Herlev, Denmark.; Hansen TW; Steno Diabetes Center, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark.; Rossing P; Steno Diabetes Center, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark.
Source
Publisher: Elsevier Science Pub. Co Country of Publication: United States NLM ID: 9204583 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-460X (Electronic) Linking ISSN: 10568727 NLM ISO Abbreviation: J Diabetes Complications Subsets: MEDLINE
Subject
Language
English
Abstract
Background: This post-hoc study investigated whether biomarkers reflecting extracellular matrix (ECM) turnover predicted cardiovascular disease (CVD), mortality, and progression of diabetic kidney disease (DKD) in individuals with type 2 diabetes (T2D) and microalbuminuria.
Methods: Serum levels of specific ECM turnover biomarkers were assessed in 192 participants with T2D and microalbuminuria from an observational study conducted at Steno Diabetes Center Copenhagen from 2007 to 2008. Endpoints included CVD events, mortality, and DKD progression, defined as decline in estimated glomerular filtration rate (eGFR) of >30 %.
Results: Participants had a mean age of 59 years, with 75 % males. Over a median follow-up of 4.9 to 6.3 years, the study recorded 38 CVD events, 24 deaths, and 40 DKD events. Elevated levels of a degradation fragment of collagen type I (C1M) were associated with an increased risk of >30 % eGFR decline, although this association was not independent of other risk factors. No significant associations were found between other ECM turnover biomarkers and DKD progression, mortality, or CVD risk.
Conclusion: Elevated C1M levels were linked to DKD progression in individuals with T2D and microalbuminuria, but not independently of other risk factors. None of the ECM turnover biomarkers were associated with CVD or mortality.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ALM, DGKR, FG, and MAK are employees of Nordic Bioscience. Nordic Bioscience is a privately owned, small- to medium-sized enterprise, partly focused on the development of biomarkers. None of the authors received fees, bonuses, or other benefits for the work regarding this article. DGKR, FG, and MAK holds stocks in Nordic Bioscience. Outside this work, BJvS is employed by Novo Nordisk, and PR has received institutional grants from Bayer, Novo Nordisk and AstraZeneca and has acted as consultant for Novo Nordisk, Bayer, Astellas, Boehringer Ingelheim, AstraZeneca, Gilead, Merk, Mundipharma, and Sanofi (honoraria to institution). The results presented in this paper have not been published previously in whole or part, except in abstract format.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Methods: Serum levels of specific ECM turnover biomarkers were assessed in 192 participants with T2D and microalbuminuria from an observational study conducted at Steno Diabetes Center Copenhagen from 2007 to 2008. Endpoints included CVD events, mortality, and DKD progression, defined as decline in estimated glomerular filtration rate (eGFR) of >30 %.
Results: Participants had a mean age of 59 years, with 75 % males. Over a median follow-up of 4.9 to 6.3 years, the study recorded 38 CVD events, 24 deaths, and 40 DKD events. Elevated levels of a degradation fragment of collagen type I (C1M) were associated with an increased risk of >30 % eGFR decline, although this association was not independent of other risk factors. No significant associations were found between other ECM turnover biomarkers and DKD progression, mortality, or CVD risk.
Conclusion: Elevated C1M levels were linked to DKD progression in individuals with T2D and microalbuminuria, but not independently of other risk factors. None of the ECM turnover biomarkers were associated with CVD or mortality.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: ALM, DGKR, FG, and MAK are employees of Nordic Bioscience. Nordic Bioscience is a privately owned, small- to medium-sized enterprise, partly focused on the development of biomarkers. None of the authors received fees, bonuses, or other benefits for the work regarding this article. DGKR, FG, and MAK holds stocks in Nordic Bioscience. Outside this work, BJvS is employed by Novo Nordisk, and PR has received institutional grants from Bayer, Novo Nordisk and AstraZeneca and has acted as consultant for Novo Nordisk, Bayer, Astellas, Boehringer Ingelheim, AstraZeneca, Gilead, Merk, Mundipharma, and Sanofi (honoraria to institution). The results presented in this paper have not been published previously in whole or part, except in abstract format.
(Copyright © 2024 Elsevier Inc. All rights reserved.)